Inorganic Chemistry
Article
decanted, and aqueous ammonium hydroxide (20 mL, 0.1 M) and
sodium ethylenediaminetetraacetate (20 mL, 0.1 M) solutions were
added to the aqueous phase. The aqueous phase was extracted with
DCM (3 × 50 mL). The organic phases were combined, dried over
sodium sulfate, filtered, and evaporated. The residue was purified by
column chromatography on silica gel (eluent 3:2 cyclohexane/ethyl
acetate) to yield a pale yellow solid (270 mg, 48% chemical yield).
Characterizations were in accordance with those published in Bolje et
al.22
[ 2 - ( 1 - ( p - T o l y l ) - 1 H - 1 , 2 , 3 - t r i a z o l - 4 - y l ) p y r i d i n e ] -
chlorotricarbonylrhenium(I) (2). This complex was obtained follow-
ing the general procedure A starting from 2-[1-(p-tolyl)-1H-1,2,3-
triazol-4-yl]pyridine (74 mg, 0.31 mmol, 1.1 equiv). The desired
product precipitated as a pale yellow solid (154 mg, quantitative).
1H NMR (300 MHz, CD3CN): δ (ppm) 9.06 (s, 1H), 9.00 (ddd, J
= 5.5, 1.4, 0.8 Hz, 1H), 8.18 (ddd, J = 7.9, 7.8, 1.4 Hz, 1H), 8.08 (ddd,
J = 7.9, 1.4, 0.8 Hz, 1H), 7.78 (m, 2H), 7.55 (ddd, J = 7.8, 5.5, 1.4 Hz,
1H), 7.49 (m, 2H), 2.46 (s, 3H). 13C{1H} NMR (75 MHz, CD3CN):
δ (ppm) 154.2, 150.3, 150.0, 142.2, 141.5, 131.6, 127.4, 124.2, 123.5,
121.9, 21.3. MS (ESI+) m/z (%): 525.0544 (100) [M − Cl + water]+,
507.0435 (75) [M − Cl]+, 565.0011 (25) [M + Na]+. HRMS (ESI+)
calcd for C17H12ClN4NaO3Re 565.0039, found 565.0011. HPLC (50
153.3, 153.0, 148.2, 147.8, 147.0, 146.8, 140.9, 132.0, 129.9, 126.9,
124.0, 123.9, 122.8, 36.5, 36.4, 35.0, 31.9. MS (ESI+) m/z (%):
719.1761 (100) [M
+
Na]+. HRMS (ESI+) calcd for
C28H34ClN4NaO3Re 719.1761, found 719.1761. HPLC (80 to 100%
MeCN in 10 min): rt 4.77 (>95%). IR: νmax/cm−1 2023, 1925, 1883,
1868 (CO).
4-Nitro-2-(trimethylsilyl)ethynyl)pyridine. 2-Bromo-4-nitropyri-
dine (437.0 mg, 2.15 mmol, 1.0 equiv) was dissolved with DMF
(3.0 mL) and Et3N (1.0 mL). The mixture was bubbled with argon for
15 min. Bis(triphenylphosphine)palladium(II) dichloride (16.6 mg,
0.0236 mmol, 1.1 mol %) and CuI (1.7 mg, 0.0086 mmol, 0.4 mol %)
were added under an atmosphere of argon, followed by trimethylsi-
lylacetylene (365 μL, 2.58 mmol, 1.2 equiv). The mixture was stirred
at 60 °C under argon for 4 h. The mixture was diluted with DCM and
washed with saturated aqueous ammonium chloride solution (2×) and
saturated brine. The organic phase was dried over sodium sulfate,
filtered, and evaporated. The residue was purified by column
chromatography on silica gel (eluent 9:1 cyclohexane/ethyl acetate)
to afford the product as a pale brown solid (395.0 mg, 83% chemical
yield). Characterizations were in accordance with those published in
Carlsson et al.23
2-Ethynyl-4-methoxypyridine. 4-Nitro-2-(trimethylsilyl)ethynyl)-
pyridine (375.0 mg, 1.7 mmol, 1.0 equiv) was dissolved in methanol
(30.0 mL), and potassium carbonate (247.0 mg, 1.79 mmol, 1.05
equiv) was added. The mixture was stirred at room temperature under
argon for 3 h. The mixture was diluted wih DCM and water and
extracted with DCM (2×). The combined organic phases were dried
over sodium sulfate, filtered, and evaporated. The residue was purified
by column chromatography on silica gel (eluent 7:3 cyclohexane/ethyl
acetate) to afford 2-ethynyl-4-methoxypyridine as a brown oil (166.0
mg, 73% chemical yield). Characterizations were in accordance with
those published in Carlsson et al.23
to 100% MeCN in 10 min): retention time (rt) 4.94 (>95%). IR: νmax
/
cm−1 2027, 1943, 1920, 1892 (CO).
2,4,6-Tri-tert-butylphenylazide. 2,4,6-Tri-tert-butylaniline (400 mg,
1.5 mmol, 1.0 equiv) was dissolved in anhydrous MeCN (4 mL) under
argon. The solution was cooled to 0 °C, and tert-butyl nitrite (274 μL,
2.3 mmol, 1.5 equiv) was added dropwise, followed by azidotrime-
thylsilane (238 μL, 1.8 mmol, 1.2 equiv) dropwise. After the solution
was stirred overnight at room temperature, the solvent was evaporated
to dryness, and the residue was purified by column chromatography on
silica gel (eluent 2:1 cyclohexane/DCM) to yield a white crystalline
solid (313 mg, 75% chemical yield)).
2-(1-Dodecyl-1H-1,2,3-triazol-4-yl)-4-methoxypyridine. 2-Ethyn-
yl-4-methoxypyridine (21.0 mg, 0.16 mmol, 1.0 equiv) and 1-
azidododecane (36.0 mg, 0.17 mmol, 1.05 equiv) were dissolved in
a mixture of DCM (1.0 mL) and water (0.6 mL). Copper(II) sulfate
pentahydrate (4.0 mg, 0.016 mmol, 0.1 equiv) and sodium ascorbate
(9.0 mg, 0.048 mmol, 0.3 equiv) were added under argon, and the
mixture was stirred at room temperature for 23 h. The mixture was
diluted with DCM and water and decanted. The organic phase was
dried over sodium sulfate, filtered, and evaporated. The residue was
purified by column chromatography (eluent ethyl acetate) to afford 2-
(1-dodecyl-1H-1,2,3-triazol-4-yl)-4-methoxypyridine as a white solid
(30.3 mg, 55% chemical yield).
Rf (2:1 cyclohexane/DCM) = 0.93. 1H NMR (300 MHz, CDCl3): δ
(ppm) 7.35 (s, 2H), 1.48 (s, 18H), 1.32 (s, 9H). 13C{1H} NMR (75
MHz, CDCl3): δ (ppm) 148.3, 145.3, 134.9, 122.5, 36.2, 35.0, 31.4,
31.3. MS (ESI+) m/z (%): 260.2370 (100) [M-N2 + H]+. HRMS (ESI
+) calcd for C18H30N 260.2378, found 260.2370.
2-(1-(2,4,6-Tri-tert-butylphenyl)-1H-1,2,3-triazol-4-yl)pyridine.
2,4,6-Tri-tert-butylphenylazide (50.0 mg, 0.17 mmol, 1.0 equiv) and 2-
ethynylpyridine (18.0 mg, 0.17 mmol, 1.0 equiv) were dissolved in 1:1
DCM/water (4 mL) mixture. Copper(II) sulfate pentahydrate (4.3
mg, 0.017 mmol, 0.1 equiv) and sodium ascorbate (6.8 mg, 0.035
mmol, 0.2 equiv) in water (0.5 mL) were added to the mixture. After it
was stirred for 48 h, DCM (10 mL) was added to the mixture. The
organic phase was decanted out and aqueous ammonium hydroxide
(10 mL, 0.1 M) and sodium ethylenediaminetetraacetate (10 mL, 0.1
M) solutions were added to the aqueous phase. The aqueous phase
was extracted with DCM (3 × 10 mL). The organic phases were
combined, dried over sodium sulfate, filtered and evaporated. The
residue was purified by column chromatography on silica gel (eluent
4:1 cyclohexane/ethyl acetate) to yield a white crystalline solid (30
mg, 45% chemical yield).
1
Rf (eluent ethyl acetate) = 0.71. H NMR (300 MHz, CDCl3): δ
(ppm): 8.37 (d, J = 5.8 Hz, 1H), 8.21 (s, 1H), 7.76 (d, J = 2.6 Hz,
1H), 6.78 (dd, J = 5.8, 2.6 Hz, 1H), 4.40 (t, J = 7.2 Hz, 2H), 3.94 (s,
3H), 1.94 (quint, J = 7.6 Hz, 2H), 1.51−1.10 (m, 18H), 0.86 (t, J = 6.0
Hz, 3H). 13C{1H} NMR (75 MHz, CDCl3): δ (ppm): 166.9, 151.8,
150.0, 147.8, 122.4, 110.5, 105.3, 55.6, 50.7, 32.0, 30.4, 29.7, 29.6, 29.5,
29.45, 29.1, 26.6, 22.8, 14.2. MS (ESI+) m/z (%): 345.2652 (100) [M
+ H]+. HRMS (ESI+) calcd for C20H33N4O 345.2654, found
345.2652.
[2-(1-Dodecyl-1H-1,2,3-triazol-4-yl)-4-methoxypyridine]-
chlorotricarbonylrhenium(I) (5). This complex was obtained follow-
ing the general procedure A starting from 2-(1-dodecyl-1H-1,2,3-
triazol-4-yl)-4-methoxypyridine (24 mg, 0.07 mmol, 1.0 equiv). The
residue was dried under reduced pressure and purified by column
chromatography on silica gel (eluent ethyl acetate) to yield the
product as a pale yellow solid (41.7 mg, 92% chemical yield).
1H NMR (300 MHz, CDCl3): δ (ppm): 8.70 (d, J = 6.4 Hz, 1H),
8.41 (s, 1H), 7.35 (d, J = 2.7 Hz, 1H), 6.86 (dd, J = 6.4, 2.7 Hz, 1H),
4.39−4.23 (m, 1H), 4.14−3.98 (m, 1H), 3.91 (s, 3H), 1.93−1.82 (m,
2H), 1.46−1.16 (m, 18H), 0.87 (t, J = 7.5 Hz, 3H). 13C{1H} NMR (75
MHz, CDCl3): δ (ppm): 167.8, 153.8, 151.3, 149.1, 124.4, 113.1,
107.3, 57.4, 52.3, 32.0, 30.1, 29.7, 29.6, 29.5, 29.4, 29.0, 26.5, 22.8,
14.3. MS (ESI+) m/z (%): 673.1538 (100) [M + Na]+. HRMS (ESI
+): calcd for C23H32ClN4NaO4Re 673.1567, found 673.1538. HPLC
(80 to 100% ACN in 10 min): rt 6.15 (>95%). IR: νmax/cm−1 2019,
1885 (CO).
1
Rf (4:1 cyclohexane/ethyl acetate) = 0.53. H NMR (300 MHz,
CDCl3): δ (ppm) 8.61 (ddd, J = 4.8, 1.7, 1.0 Hz, 1H), 8.33 (s, 1H),
8.29 (dt, J = 7.9, 1.0 Hz, 1H), 7.81 (td, J = 7.9, 1.7 Hz, 1H), 7.57 (s,
2H), 7.27 (td, J = 4.8, 1.0 Hz, 1H), 1.38 (s, 9H), 1.01 (s, 18H).
13C{1H} NMR (75 MHz, CDCl3): δ (ppm) 152.0, 150.3, 149.5, 147.5,
147.1, 136.9, 131.7, 129.1, 123.7, 122.9, 120.4, 36.9, 35.3, 32.2, 31.3.
MS (ESI+) m/z (%): 391.2857 (100) [M + H]+, 413.2671 (30) [M +
Na]+. HRMS (ESI+) calcd for C25H35N4 391.2856, found 391.2857.
[2-(1-(2,4,6-Tri-tert-butylphenyl)-1H-1,2,3-triazol-4-yl)pyridine]-
chlorotricarbonylrhenium(I) (3). This complex was obtained follow-
ing the general procedure A starting from 2-[1-(2,4,6-tri-tert-
butylphenyl)-1H-1,2,3-triazol-4-yl]pyridine (14 mg, 0.036 mmol, 1.1
equiv). The desired product precipitated as a cream solid (20 mg, 85%
chemical yield).
1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.76 (s, 1H), 9.01 (m,
1H), 8.33 (m, 2H), 7.77 (m, 1H), 7.63 (s, 2H), 1.37 (s, 9H), 1.07 (s,
9H), 1.05 (s, 9H). 13C{1H} NMR (75 MHz, DMSO-d6): δ (ppm)
C
Inorg. Chem. XXXX, XXX, XXX−XXX